<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822496</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00737</org_study_id>
    <secondary_id>NCI-2013-00737</secondary_id>
    <secondary_id>RTOG 1306</secondary_id>
    <secondary_id>RTOG-1306</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <nct_id>NCT01822496</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with
      chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.
      Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy
      that delivers a high dose of radiation directly to the tumor may kill more tumor cells and
      cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin,
      etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than
      crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess whether patients with unresectable local-regionally advanced non-small cell
      lung cancer (NSCLC) treated with targeted agents based on molecular characteristics have a
      longer progression-free survival than those treated with standard care therapy alone.

      SECONDARY OBJECTIVES:

      I. To evaluate response rate. II. To assess toxicity. III. To assess overall survival. IV.
      To correlate clinical outcomes with tumor molecular aberrations identified from deep
      sequencing of selected kinomes in patients from whom adequate baseline tissue is available.

      OUTLINE: Patients are randomized to 1 of 4 treatment arms.

      ARM I (induction therapy): Patients receive erlotinib hydrochloride orally (PO) once daily
      (QD) for up to 12 weeks. Patients who have had no response (partial or complete) after 6
      weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of
      induction therapy, patients receive chemoradiation.

      ARM III (induction therapy): Patients receive crizotinib PO twice daily (BID) for up to 12
      weeks. Patients who have had no response (partial or complete) after 6 weeks undergo
      concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction
      therapy, patients receive chemoradiation.

      ARMS II AND IV (concurrent chemoradiation): Patients receive concurrent chemotherapy with
      thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease
      progression or unacceptable toxicity.

      CHEMORADIATION: In all treatment arms, patients undergo concurrent intensity modulated
      radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3-D CRT) QD 5 days a
      week for 6 weeks. Patients receive 1 of 2 chemotherapy regimens based on the discretion of
      the treating physician. Patients receive cisplatin intravenously (IV) over 1-2 hours on days
      1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Treatment repeats every
      4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
      Some patients receive paclitaxel IV and carboplatin IV on days 1, 8, 15, 22, 29, and 36
      during radiation therapy for 6 weeks. Two courses of consolidation treatment will begin 4-6
      weeks after completion of radiation therapy with paclitaxel IV on days 1 and 22 and
      carboplatin IV on days 1 and 22 in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up at 1 month, every 3 months for
      2 years, every 6 months for 3 years, and then annually for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Occurrence of local or regional progression, distant metastases, or death from any cause from the time of randomization to the occurrence of one of the failure events, whichever occurs first, assessed up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The product limit estimator developed by Kaplan and Meier will be used. Their 95% confidence intervals will be estimated. Comparisons between arms will be conducted using a log rank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor molecular aberrations identified from deep sequencing of selected kinomes will be correlated with clinical outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant progression free survival</measure>
    <time_frame>Time from randomization to distant progression or death, whichever occurs first, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Appropriate methods for competing risks will be applied, specifically cumulative incidence functions for estimation of cumulative cause specific event probabilities with associated testing for differences, and regression methods for cause-specific hazards and subdistribution hazards underlying cumulative incidence functions may be applied accordingly for exploratory purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-5 adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Summarized using frequency table methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional progression free survival</measure>
    <time_frame>Time from randomization to local-regional progression or death, whichever comes first, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Appropriate methods for competing risks will be applied, specifically cumulative incidence functions for estimation of cumulative cause specific event probabilities with associated testing for differences, and regression methods for cause-specific hazards and subdistribution hazards underlying cumulative incidence functions may be applied accordingly for exploratory purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time to death from any cause, assessed up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The product limit estimator developed by Kaplan and Meier will be used. Their 95% confidence intervals will be estimated. Comparisons between arms will be conducted using a log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who respond (completely or partially) to each treatment, assessed by the Response Evaluation Criteria in Solid Tumors</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated as well as their 95% confidence intervals. Response rate will be tested using Fisher's exact test and using a logistic regression model to incorporate other prognostic covariates.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Stage IIIA Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO QD for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive crizotinib PO BID for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3-D CRT</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>3-dimensional radiation therapy</other_name>
    <other_name>3D CONFORMAL RADIATION THERAPY</other_name>
    <other_name>3D CRT</other_name>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <other_name>MET Tyrosine Kinase Inhibitor PF-02341066</other_name>
    <other_name>PF-02341066</other_name>
    <other_name>PF-2341066</other_name>
    <other_name>Xalkori</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <other_name>Cp-358,774</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC

          -  Unresectable stage IIIA or IIIB disease; patients must be surgically staged to
             confirm N2 or N3 disease; patients may have invasive mediastinal staging by
             mediastinoscopy, mediastinotomy, endobronchial ultrasound transbronchial aspiration
             (EBUS-TBNA), endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery
             (VATS)

          -  Patients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3,
             N1-N3 disease are eligible if deemed unresectable; patients with T4, any N are
             eligible

          -  Patients must have measurable disease, i.e., lesions that can be accurately measured
             in at least 1 dimension (longest dimension in the plane of measurement is to be
             recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan
             slice thickness no greater than 5 mm)

          -  Patients with a pleural effusion, which is a transudate, cytologically negative and
             non-bloody, are eligible if the radiation oncologist feels the tumor can be
             encompassed within a reasonable field of radiotherapy

          -  If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too
             small to tap, the patient will be eligible; patients who develop a new pleural
             effusion after thoracotomy or other invasive thoracic procedure will be eligible

          -  The institution's pre-enrollment biomarker screening at a Clinical Laboratory
             Improvement Amendments (CLIA) certified lab documents presence of known &quot;sensitive&quot;
             mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon
             19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement;
             either the primary tumor or the metastatic lymph node tissue may be used for testing
             of mutations

          -  The institution's pre-enrollment biomarker screening at a CLIA certified lab
             documents absence of T790M mutation in the EGFR TK domain

          -  Appropriate stage for protocol entry, including no distant metastases, based upon the
             following minimum diagnostic workup:

               -  History/physical examination, including recording of pulse, blood pressure (BP),
                  weight, and body surface area, within 45 days prior to registration

               -  Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to
                  mid-thighs) within 30 days prior to registration; PET/CT must be negative for
                  distant metastasis

               -  CT scan with contrast of the chest and upper abdomen to include liver and
                  adrenals (unless medically contraindicated) within 30 days prior to registration

               -  Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with
                  contrast, if MRI medically contraindicated) within 30 days prior to registration

          -  Zubrod performance status 0-1 within 14 days prior to registration

          -  Absolute neutrophil count (ANC) &gt;= 1,000 cells/mm^3

          -  Platelets &gt;= 100,000 cells/mm^3

          -  Hemoglobin &gt;= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] &gt;= 8.0 g/dl is acceptable)

          -  Serum creatinine &lt; 1.5 mg/dL or calculated creatinine clearance &gt;= 50 ml/min (by
             Cockcroft-Gault formula) within 14 days prior to registration

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 2.5 x upper limit
             of normal (ULN) within 14 days prior to registration

          -  Bilirubin within normal institutional limits within 14 days prior to registration

          -  Negative serum pregnancy test within 14 days prior to registration for women of
             childbearing potential

          -  Patient must provide study specific informed consent prior to study entry, including
             consent for mandatory screening of tissue

        Exclusion Criteria:

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast,
             oral cavity, or cervix are all permissible)

          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Atelectasis of the entire lung

          -  Contralateral hilar node involvement

          -  Exudative, bloody, or cytologically malignant effusions

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of
                  registration; hepatic insufficiency resulting in clinical jaundice and/or
                  coagulation defects

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for
                  Disease Control and Prevention (CDC) definition; note, however, that human
                  immunodeficiency virus (HIV) testing is not required for entry into this
                  protocol; protocol-specific requirements may also exclude immuno-compromised
                  patients

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception

          -  Prior allergic reaction to the study drug(s) involved in this protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramaswamy Govindan</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Alaska Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew C. Solhjem</last_name>
      <phone>503-215-6387</phone>
      <email>Julie.Cramer@providence.org</email>
    </contact>
    <investigator>
      <last_name>Matthew C. Solhjem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda I. Garces</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Yolanda I. Garces</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy W. Loo</last_name>
      <phone>650-498-7061</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Billy W. Loo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Tate</last_name>
      <phone>707-967-5722</phone>
      <email>David.Tate@ah.org</email>
    </contact>
    <investigator>
      <last_name>David J. Tate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue S. Yom</last_name>
      <phone>415-353-9883</phone>
      <email>yoms@radonc.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Sue S. Yom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian D. Kavanagh</last_name>
      <phone>720-848-0650</phone>
    </contact>
    <investigator>
      <last_name>Brian D. Kavanagh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penrose-Saint Francis Healthcare</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>303-777-2642</phone>
      <email>kgeisen@co-cancerresearch.org</email>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane W. Ridings</last_name>
      <phone>719-365-2406</phone>
    </contact>
    <investigator>
      <last_name>Jane W. Ridings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian D. Kavanagh</last_name>
      <phone>720-848-0650</phone>
    </contact>
    <investigator>
      <last_name>Brian D. Kavanagh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McKee Medical Center</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>303-777-2642</phone>
      <email>kgeisen@co-cancerresearch.org</email>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal B. Goldberg</last_name>
      <phone>860-224-5986</phone>
      <email>neal.goldberg@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Neal B. Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal B. Goldberg</last_name>
      <phone>860-224-5986</phone>
      <email>neal.goldberg@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Neal B. Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Raben</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Adam Raben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Castellon</last_name>
      <phone>954-844-6808</phone>
      <email>igcastellon@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Castellon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark E. Augspurger</last_name>
      <phone>904-271-6695</phone>
      <email>mark.augspurger@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Mark E. Augspurger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark E. Augspurger</last_name>
      <phone>904-271-6695</phone>
      <email>mark.augspurger@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Mark E. Augspurger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian S. Ishkanian</last_name>
      <phone>866-574-5124</phone>
      <email>Sylvester@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Adrian S. Ishkanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Rineer</last_name>
      <phone>321-841-7246</phone>
      <email>CancerClinicalTrials@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Justin Rineer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology-Palatka</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network-Flager Cancer Center</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Robert and Carol Weissman Cancer Center at Martin Health</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>404-778-4139</phone>
      <email>kristin.higgins@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>404-778-4139</phone>
      <email>kristin.higgins@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank G. Lake</last_name>
      <phone>770-219-8800</phone>
      <email>cancerpatient.navigator@nghs.com</email>
    </contact>
    <investigator>
      <last_name>Frank G. Lake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lewis Cancer and Research Pavilion at Saint Joseph's/Candler</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Pablo</last_name>
      <phone>800-622-6877</phone>
    </contact>
    <investigator>
      <last_name>John A. Pablo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Center of Hawaii-Liliha</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Cancer Care Center-Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nisha A. Mohindra</last_name>
      <phone>312-695-6189</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Nisha A. Mohindra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria M. Villaflor</last_name>
      <phone>773-702-3002</phone>
      <email>vvillafl@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Victoria M. Villaflor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew M. Harkenrider</last_name>
      <phone>708-216-6076</phone>
      <email>mharkenrider@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew M. Harkenrider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward Hospital/Cancer Center</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria I. Quejada</last_name>
      <phone>630-646-6071</phone>
      <email>mquejada@edward.org</email>
    </contact>
    <investigator>
      <last_name>Maria I. Quejada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward Hospital/Cancer Center?Plainfield</name>
      <address>
        <city>Plainfield</city>
        <state>Illinois</state>
        <zip>60585</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria I. Quejada</last_name>
      <phone>630-646-6071</phone>
      <email>mquejada@edward.org</email>
    </contact>
    <investigator>
      <last_name>Maria I. Quejada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Anderson Regional Hospital/Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander M. Yeh</last_name>
      <phone>765-646-8413</phone>
      <email>amyeh@stvincent.org</email>
    </contact>
    <investigator>
      <last_name>Alexander M. Yeh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Associates PC</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian K. Chang</last_name>
      <phone>260-373-8888</phone>
      <email>parkviewresearch@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Brian K. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital Randallia</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian K. Chang</last_name>
      <phone>260-373-8888</phone>
      <email>parkviewresearch@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Brian K. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-William R Bliss Cancer Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aruna Turaka</last_name>
      <phone>319-297-2900</phone>
      <email>arunaturaka@opog.com</email>
    </contact>
    <investigator>
      <last_name>Aruna Turaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siouxland Regional Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald B. Wender</last_name>
      <phone>712-252-9359</phone>
      <email>drednew@msn.com</email>
    </contact>
    <investigator>
      <last_name>Donald B. Wender</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center- Scarborough Campus</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian J. Bristol</last_name>
      <phone>207-396-8090</phone>
      <email>wrighd@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Ian J. Bristol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Feigenberg</last_name>
      <phone>800-888-8823</phone>
    </contact>
    <investigator>
      <last_name>Steven J. Feigenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette A. Linder</last_name>
      <phone>410-601-6120</phone>
      <email>pridgely@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeanette A. Linder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn E. Huber</last_name>
      <phone>617-636-8886</phone>
      <email>ContactUsCancerCenter@TuftsMedicalCenter.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn E. Huber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey R. Oxnard</last_name>
      <phone>877-442-3324</phone>
      <email>goxnard@partners.org</email>
    </contact>
    <investigator>
      <last_name>Geoffrey R. Oxnard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey R. Oxnard</last_name>
      <phone>617-632-5786</phone>
      <email>goxnard@partners.org</email>
    </contact>
    <investigator>
      <last_name>Geoffrey R. Oxnard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob M. Sands</last_name>
      <phone>781-744-5192</phone>
      <email>jacob.m.sands@lahey.org</email>
    </contact>
    <investigator>
      <last_name>Jacob M. Sands</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blair Ardman</last_name>
      <phone>978-788-7084</phone>
      <email>ghincks@lowellgeneral.org</email>
    </contact>
    <investigator>
      <last_name>Blair Ardman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital and Medical Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health Saint Mary's</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-391-1230</phone>
      <email>connie.szczepanek@grcop.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-954-2116</phone>
      <email>connie.szczepanek@grcop.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-954-2116</phone>
      <email>connie.szczepanek@grcop.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's of Michigan</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-4673</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miller-Dwan Hospital</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
      <email>bret.friday@essentiahealth.org</email>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda I. Garces</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Yolanda I. Garces</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rice Memorial Hospital</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Phelps County Regional Medical Center</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>417-820-3587</phone>
      <email>jay.carlson@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramaswamy Govindan</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ramaswamy Govindan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>417-820-3587</phone>
      <email>jay.carlson@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien-Shew W. Huang</last_name>
      <phone>402-354-5144</phone>
    </contact>
    <investigator>
      <last_name>Tien-Shew W. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elliot Hospital</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian R. Knab</last_name>
      <phone>603-663-1800</phone>
      <email>brknab@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Brian R. Knab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Memorial</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <phone>609-914-6762</phone>
    </contact>
    <investigator>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salma K. Jabbour</last_name>
      <phone>732-235-8675</phone>
      <email>jabbousk@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Salma K. Jabbour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salma K. Jabbour</last_name>
      <phone>732-235-8675</phone>
      <email>jabbousk@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Salma K. Jabbour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. D'Ambrosio</last_name>
      <phone>732-818-3882</phone>
    </contact>
    <investigator>
      <last_name>David J. D'Ambrosio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Mary Imogene Bassett Hospital</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy E. Anderson</last_name>
      <phone>607-547-3073</phone>
      <email>diana.crean@bassett.org</email>
    </contact>
    <investigator>
      <last_name>Joy E. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge E. Gomez</last_name>
      <phone>212-824-7320</phone>
      <email>jenny.figueroa@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge E. Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care of Western North Carolina</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher H. Chay</last_name>
      <phone>828-418-0932</phone>
      <email>chay@ccwnc.com</email>
    </contact>
    <investigator>
      <last_name>Christopher H. Chay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital-Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher H. Chay</last_name>
      <phone>828-418-0932</phone>
      <email>chay@ccwnc.com</email>
    </contact>
    <investigator>
      <last_name>Christopher H. Chay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian E. Lally</last_name>
      <phone>336-713-6622</phone>
      <email>blally@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Brian E. Lally</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital/Cooper Cancer Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree E. Doncals</last_name>
      <phone>330-375-6101</phone>
    </contact>
    <investigator>
      <last_name>Desiree E. Doncals</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchel L. Fromm</last_name>
      <phone>330-344-6348</phone>
    </contact>
    <investigator>
      <last_name>Mitchel L. Fromm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Barberton Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree E. Doncals</last_name>
      <phone>330-375-6101</phone>
    </contact>
    <investigator>
      <last_name>Desiree E. Doncals</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adena Regional Medical Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center/Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng X. Welliver</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Meng X. Welliver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mark H Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center-Elyria</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center Independence</name>
      <address>
        <city>Independence</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Care</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center Strongsville</name>
      <address>
        <city>Strongsville</city>
        <state>Ohio</state>
        <zip>44136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Wooster Family Health and Surgery Center</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence S. Herman</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Terence S. Herman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at Saint Francis</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Legacy Mount Hood Medical Center</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y. Kee</last_name>
      <phone>800-220-4937</phone>
      <email>cancer@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Y. Kee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital and Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y. Kee</last_name>
      <phone>800-220-4937</phone>
      <email>cancer@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Y. Kee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew C. Solhjem</last_name>
      <phone>503-215-6387</phone>
      <email>Julie.Cramer@providence.org</email>
    </contact>
    <investigator>
      <last_name>Matthew C. Solhjem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salem Hospital</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Strother</last_name>
      <phone>503-561-2618</phone>
    </contact>
    <investigator>
      <last_name>John Strother</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>484-476-2649</phone>
      <email>ewend@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Gergel</last_name>
      <phone>570-271-5251</phone>
    </contact>
    <investigator>
      <last_name>Thomas J. Gergel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paoli Memorial Hospital</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>484-476-2649</phone>
      <email>ewend@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A. Hallman</last_name>
      <phone>215-214-1629</phone>
      <email>mark.hallman@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark A. Hallman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Group PC-Robert Packer Hospital</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley W. Lash</last_name>
      <phone>800-836-0388</phone>
      <email>lash_bradley@guthrie.org</email>
    </contact>
    <investigator>
      <last_name>Bradley W. Lash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>484-476-2649</phone>
      <email>ewend@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol A. Sherman</last_name>
      <phone>843-792-0644</phone>
      <email>shermanc@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Carol A. Sherman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C. Griffin</last_name>
      <phone>828-560-1055</phone>
      <email>pgriffin@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Patricia C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hak Choy</last_name>
      <phone>214-645-8913</phone>
      <email>hak.choy@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Hak Choy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne S. Tsao</last_name>
      <phone>713-792-3245</phone>
    </contact>
    <investigator>
      <last_name>Anne S. Tsao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covenant Medical Center-Lakeside</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J. Anderson</last_name>
      <phone>806-725-8000</phone>
      <email>jaccresearch@covhs.org</email>
    </contact>
    <investigator>
      <last_name>Paul J. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George M. Cannon</last_name>
      <phone>801-507-3810</phone>
      <email>george.cannon2@imail.org</email>
    </contact>
    <investigator>
      <last_name>George M. Cannon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dixie Medical Center Regional Cancer Center</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George M. Cannon</last_name>
      <phone>801-507-3810</phone>
      <email>george.cannon2@imail.org</email>
    </contact>
    <investigator>
      <last_name>George M. Cannon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Medical Center</name>
      <address>
        <city>Longview</city>
        <state>Washington</state>
        <zip>98632</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew C. Solhjem</last_name>
      <phone>503-215-6387</phone>
      <email>Julie.Cramer@providence.org</email>
    </contact>
    <investigator>
      <last_name>Matthew C. Solhjem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Southwest Medical Center</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew C. Solhjem</last_name>
      <phone>503-215-6387</phone>
      <email>Julie.Cramer@providence.org</email>
    </contact>
    <investigator>
      <last_name>Matthew C. Solhjem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edwards Comprehensive Cancer Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria R. Tria Tirona</last_name>
      <phone>304-399-6617</phone>
    </contact>
    <investigator>
      <last_name>Maria R. Tria Tirona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Community Memorial Hospital</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Saint Mary's Hospital - Ozaukee</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53097</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Saint Mary's Water Tower Medical Commons</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wingate F. Clapper</last_name>
      <phone>262-928-7537</phone>
      <email>Chanda.miller@phci.org</email>
    </contact>
    <investigator>
      <last_name>Wingate F. Clapper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alyce and Elmore Kraemer Cancer Care Center</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>May 26, 2016</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
